Klaus Gregorius

Title: Innovations by Klaus Gregorius: Pioneering the Field of Molecular Imprinted Polymers

Introduction

Klaus Gregorius, an accomplished inventor based in Søborg, Denmark, has made significant contributions in the realm of molecular imprinted polymers. With a total of 8 patents to his name, his work primarily focuses on targeting metabolic malfunctions and enhancing the detection of specific molecules.

Latest Patents

Klaus Gregorius' recent patents include groundbreaking technologies such as "Molecular Imprinted Polymers Targeting Phenylalanine." This invention presents agents and methods aimed at addressing both inherited and acquired metabolic disorders. It details methods for creating molecular imprinted polymers (MIPs) with a high binding capacity for phenylalanine and tyrosine, and explores therapeutic options for treating conditions such as phenylketonuria, alkaptonuria, and hypertyrosinemia.

Another notable patent from Klaus is "Detection Method and Means Therefor," which discloses a Förster resonance energy transfer (FRET) based assay and related products. This assay employs highly selective molecular imprinted polymers that exhibit a strong affinity for their targets, showcasing his innovative approach to analytical detection.

Career Highlights

Throughout his career, Klaus Gregorius has worked with prominent companies in the field. He has contributed his expertise to Mipsalus ApS and Medtronic MiniMed, Inc., where he has been instrumental in advancing research and development initiatives in the health technology sector.

Collaborations

Klaus has collaborated with esteemed colleagues such as Nicolas Otto Krogh and Jesper Svenning Kristensen. Their synergistic efforts in research have contributed to several innovations within the field of molecular imprinting, demonstrating a strong team dynamic that has propelled their projects to success.

Conclusion

Klaus Gregorius stands out as a remarkable inventor whose work on molecular imprinted polymers is paving the way for novel solutions in metabolic disorder management and detection methodologies. His 8 patents reflect a commitment to research excellence and a passion for innovation that continues to inspire future advancements in this vital area of study.